In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $145.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Abbott Laboratories’ strong financial performance and growth potential. Despite facing significant tariff impacts, the company has maintained its guidance for 2025, projecting robust earnings per share, operating margins, and organic sales growth.
Abbott’s first-quarter results exceeded expectations, with notable revenue and earnings per share figures. The company’s Medical Devices segment showed impressive organic growth, particularly in Diabetes Care, where continuous glucose monitoring sales surged. Although the Diagnostics segment underperformed due to challenges in China, the overall growth outside this region remained strong, indicating that the issues are localized and not indicative of broader weaknesses.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $140.00 price target.